Trial Profile
First-line treatment with bevacizumab in patients with metastatic colorectal cancer: the significance of EGFR pathway mutations for efficacy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Aug 2015 New trial record